Figure 5.

Relative percentage of on-target tumor accumulation of the myeloid cells where the tumor-associated accumulation, quantified by the in vivo accumulation factor, of each cell type is represented as the percentage of the combined signal present in the tumor versus liver and spleen (tumor/(tumor + liver and spleen)). Significant differences: monocytes versus MDSCs from 4T1 tumor-bearing donor (at 24 h, 72 h and 96 h; p<0.05), monocytes versus bone marrow cells from healthy donor (at 96 h, p<0.05), monocytes versus in vitro differentiated MDSCs (at 48 h, p<0.05), macrophages versus bone marrow cells from healthy donor (at 96 h, p<0.05) and macrophages versus MDSCs from 4T1 tumor-bearing donor (at 96 h, p<0.01). MDSCs: myeloid-derived suppressor cells.